Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons
详细信息 查看全文
- 作者：Souvik Karmakar ; Weidong Zhang ; Gul Ahmad ; Workineh Torben ; Mayeen U. Alam ; Loc Le ; Raymond T. Damian ; Roman F. Wolf ; Gary L. White ; David W. Carey ; Darrick Carter ; Steven G. Reed ; Afzal A. Siddiqui
- 关键词：Schistosome vaccine ; Intestinal schistosomiasis ; Urinary schistosomiasis ; Schistosoma mansoni ; Schistosoma haematobium ; Sm-p80 ; Calpain ; Nonhuman primate ; Baboons
- 刊名：Vaccine
- 出版年：5 March, 2014
- 年：2014
- 卷：32
- 期：11
- 页码：1296-1303
- 全文大小：1157 K
文摘
The ability of the Schistosoma mansoni antigen, Sm-p80, to provide cross-species protection against Schistosoma haematobium challenge was evaluated in hamster and baboon models. Pronounced reduction in worm burden (48%) and in tissue egg load (64%) was observed in hamsters vaccinated with recombinant Sm-p80 admixed with glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE). Similarly, in baboons, the Sm-p80/GLA-SE vaccine produced a 25% reduction in S. haematobium adult worms and decreased the egg load in the urinary bladder by 64%. A 40% and 53% reduction in fecal and urine egg output, respectively, was observed in vaccinated baboons. A balanced pro-inflammatory (Th17 and Th1) and Th2 type of response was generated after vaccination and appears indicative of augmented prophylactic efficacy. These data on cross-species protection coupled with the prophylactic, therapeutic and antifecundity efficacy against the homologous parasite, S. mansoni, reinforces Sm-p80 as a promising vaccine candidate. It is currently being prepared for GMP-compliant manufacture and for further pre-clinical development leading to human clinical trials. These results solidify the expectation that the Sm-p80 vaccine will provide relief for both the intestinal and the urinary schistosomiasis and thus will be greatly beneficial in reducing the overall burden of schistosomiasis.